Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

In this video, Xiuning Le, MD, PhD, discusses the state of the pipeline for developing EGFR-mutated lung cancer treatments.

The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12 ...

Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...

Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...

The artificial intelligence community is raving over a new reasoning model that has surprised even Silicon Valley.

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

On January 27, the company announced improvements to its RADR® AI platform aimed at accelerating and optimizing the development of antibody-drug conjugates (ADCs). ADC is a process of creating ...

The study is evaluating TUB-030, Tubulis’ next-generation antibody-drug conjugate (ADC), in patients with advanced solid tumors. The ADC targets 5T4, an oncofetal antigen expressed in a broad ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, including ...